-+ 0.00%
-+ 0.00%
-+ 0.00%

*CalciMedica: Proceeds Expected to Support Pulmonary Hypertension Strategy, Including Phase 1b POC Study Evaluating Auxora in PAH, With Data Anticipated Mid-2027, and Advancement of Oral CRAC Channel Inhibitor CM5480 to IND Clearance Expected Mid-2027 >CALC

Dow Jones·06/24/2026 11:08:00

Please log in to view news